Amneal Pharmaceuticals

Last updated

Amneal Pharmaceuticals
Company type Public
NYSE:  AMRX (Class A)
Russell 2000 Component
Founded2002 (2002) [1]
Founders
  • Chirag Patel
  • Chintu Patel, R. Ph
Headquarters
Bridgewater, New Jersey
Number of locations
Manufacturing plants in Branchburg, East Hanover and Piscataway, NJ; Brookhaven and Hauppauge, NY, India and Ireland; & Distribution/Commercial Operations in Glasgow, KY [1]
ProductsGeneric and specialty pharmaceuticals; biosimilars
RevenueIncrease2.svg $US $1.6 billion (2019)
Number of employees
>6,000 [1]
Divisions
  • Generics
  • Specialty Pharma
Website amneal.com

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey. [2]

Contents

History

Amneal Pharmaceuticals was founded in 2002 by brothers Chirag and Chintu Patel. The company manufactured its first prescription product in 2005 and received its first ANDA approval[ clarification needed ] in 2006. [3]

In 2007, the company acquired five divested drugs from Mylan which Mylan was forced to sell as part of their acquisition of the generics unit of Merck KGaA. [4] At this time, the company was noted as being a private company based in Paterson, New Jersey. [4]

After the 2007 acquisition of Akyma Pharmaceuticals, a Glasgow, Kentucky-based regional distributor, Amneal launched its own product label. [5]

In 2008, the company expanded into India with the development of an R&D Centre in Gujarat. [6] Continued expansion in the United States occurred between 2010 and 2016 in New Jersey, New York and Kentucky. [7] [8] As of 2017, the company had grown much of its physical footprint and product base through a series of acquisitions, including the acquisition of assets from Pfizer, Actavis and Warner Chilcott. [3]

In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. Shares of newly public AMRX began trading on the NYSE on May 7, 2018. [9] Concurrent with the Impax merger, Amneal acquired Gemini Laboratories for $117 million, including Unithroid, Gemini's lead product for treating hypothyroidism. [10]

In December 2019, Amneal announced it had entered into an agreement to acquire a majority interest in AvKARE, a private label provider of generic pharmaceuticals in the US federal agency sector. Under the agreement, AvKARE would continue to operate as an independent subsidiary of Amneal. [11]

As of June 2020, co-founders Chirag and Chintu Patel served as co-CEOs of the company, while Paul Meister served as chairman. [12] [13]

In January 2021, the business announced it would acquire 98% of Kashiv BioSciences LLC and its drug delivery platforms. [14]

In January 2022, Amneal announced it would acquire Saol Therapeutics Baclofen franchise for around $83.5 million, plus future royalties. [15]

Formation of Amneal Pharmaceuticals Inc

In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. The FTC described the merger as having a value of US$1.45 billion, and required the companies to divest several marketed products and development projects as a condition of the approval. [16] The merger was completed in May 2018, with shares of IPXL ceasing trading on NASDAQ on May 4 and shares of AMRX commencing trading on the NYSE on May 7. [17] The company's predecessor entity, privately held Impax Pharmaceuticals, Inc., was founded in 1995. Publicly traded Global Pharmaceutical Corporation and Impax Pharmaceuticals, Inc. completed a reverse merger, forming Impax Laboratories, Inc. on December 14, 1999. [18]

List of mergers and acquisitions

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

  • Amneal Pharmaceuticals, Inc.
    • Amneal Pharmaceuticals (Merged 2018)
      • Amneal Pharmaceuticals LLC
        • Akyma Pharmaceuticals (Acq. 2007)
      • Impax Laboratories, Inc.
    • Gemini Laboratories (Acq. 2018)
    • AvKARE (Acq. 2019)
    • Kashiv BioSciences LLC (Acq. 2021)

Operations

Research and development

As of July 2019, Amneal operated seven Research and Development (R&D) centers in the United States, India and Ireland. [19] According to the company, 10% of net revenue is invested in R&D. [20]

After the Impax merger, Amneal was reportedly the fifth largest U.S. generic drug maker in the United States with a generics portfolio inclusive of more than 200 product families, approximately 149 ANDAs filed with the FDA, and 135 projects in development at that time. [21]

The company's research and development activity in the biosimilar space has included a 2017 partnership with Adello Biologics (for the collaborative development of Neupogen and Neuasta biosimilars) and a 2018 partnership with mAbxience (for the development of Avastin biosimilars). [21] [22]

Pharmaceutical products

600mg ibuprofen tablets manufactured by Amneal Pharmaceuticals Amneal Pharmaceuticals ibuprofen tablets.jpg
600mg ibuprofen tablets manufactured by Amneal Pharmaceuticals

Amneal's Generics Division focuses on a broad range of therapeutic areas, including solid oral dosage products and alternative dosage form products. [23]

The company's Specialty Pharma Division is focused on the development of proprietary branded pharmaceutical products for the treatment of Central Nervous System disorders, Endocrine disorders and other select specialty segments. [24]

This division commercializes several branded pharmaceutical products, including Rytary, an extended release oral capsule formulation for the treatment of Parkinson's disease, Unithroid, for treatment of hypothyroidism, Emverm, for treatment of certain gastrointestinal infections, and Zomig Nasal Spray, for the acute treatment of migraines. [25]

As of July 2019, the company owned ten manufacturing sites and seven R&D sites in the United States, Ireland and India. [26]

In 2020, in response to the interest in chloroquine and hydroxychloroquine during the COVID-19 pandemic, and before the United States Food and Drug Administration's emergency use authorization was withdrawn, Amneal ramped up production. [27]

In June 2023, the US FDA declined to approve a drug (carbidopa-levodopa) designed to help control symptoms in Parkinson's disease patients for a longer duration, because of inadequate safety data. [28]

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals

Alvogen is an Icelandic pharmaceutical company founded in 2009. In 2014, a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

References

  1. 1 2 3 "Amneal at-a-glance".
  2. ↑ "Amneal at-a-glance". Amneal Pharmaceuticals. Retrieved July 26, 2019.
  3. 1 2 Das, Sohini (November 14, 2017). "Founded by 2 Gujaratis, US drug major Amneal eyes speciality biz in India". Business Standard India. Business Standard.
  4. 1 2 Sabatini, Patricia (September 28, 2007). "Drug maker selling assets to win OK for deal". Business. Pittsburgh Post-Gazette. Retrieved June 23, 2018– via Newspapers.com (Publisher Extra).
  5. ↑ "With technology, research muscle, Amneal looks to make its mark". Drug Store News. September 24, 2007.
  6. ↑ "Amneal Pharmaceuticals Completes Acquisition Of Liquid Form Generic Pharmaceuticals Manufacturing Plant". Pharmaceutical Online. January 4, 2008.
  7. ↑ "Amneal Pharmaceuticals Undergoing $60 Million Expansion". Patch. July 17, 2013.
  8. ↑ "Amneal Pharmaceuticals to expand in Glasgow". Louisville Business First. May 11, 2010.
  9. ↑ "Amneal Pharmaceuticals, Inc. (AMRX)". SeekingAlpha. March 2, 2020.
  10. ↑ "Newly Merged Amneal Pharmaceuticals to Push into the Biosimilar Space". BioSpace. May 10, 2018.
  11. ↑ "Amneal to purchase majority interest in AvKARE for $340M". NJBIZ. December 10, 2019.
  12. ↑ "Paul Bisaro vaulted now-struggling Amneal to top generics ranks—now, he and his handpicked CEO are out". Fierce Pharma. August 5, 2019.
  13. ↑ "Amneal co-founders back as co-CEOs; executive chairman, CEO resign". ROI-NJ. August 6, 2019.
  14. ↑ "Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals".
  15. ↑ "Amneal Acquires Saol Therapeutics' Baclofen Franchise".
  16. ↑ "Amneal And Impax Complete Business Combination". Biosimilar Development. May 7, 2018.
  17. ↑ "How $6 billion generic drug company merger could affect this East Bay city and Roche". San Francisco Business Times. May 9, 2018.
  18. ↑ "Form 10-K Impax Laboratories, Llc". SEC.gov. March 1, 2018.
  19. ↑ "Amneal to restructure, slashing 2019 earnings estimate". BioPharma Dive. July 10, 2019.
  20. ↑ "Amneal And Impax Complete Business Combination". Biosimilar Development. May 7, 2018.
  21. 1 2 "How $6 billion generic drug company merger could affect this East Bay city and Roche". San Francisco Business Times. May 9, 2018.
  22. ↑ "Amneal and Impax Merge; Amneal Announces Biosimilar Development Agreement". AJMC. May 10, 2018.
  23. ↑ "With technology, research muscle, Amneal looks to make its mark". Drug Store News. September 24, 2007.
  24. ↑ "Shining stars: Luminaries in the generics industry". Drug Store News. July 16, 2019.
  25. ↑ "Newly Merged Amneal Pharmaceuticals to Push into the Biosimilar Space". BioSpace. May 10, 2018.
  26. ↑ "Amneal to restructure, slashing 2019 earnings estimate". BioPharma Dive. July 10, 2019.
  27. ↑ "Amneal faces hydroxychloroquine API shortage after Finland tightens production". FiercePharma. April 13, 2020.
  28. ↑ "US FDA declines to approve Amneal's Parkinson's drug over safety concerns". Reuters. July 3, 2023. Retrieved July 4, 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.